Michael Surace

Company: AstraZeneca

Job title: Director

Seminars:

Enabling Clinical Uptake of Higher-Plex Technologies in IHC/ISH 3:00 pm

• Multiplex immunohistochemistry and in situ hybridization assays are used in early therapeutic development and are becoming increasingly pervasive within the diagnostic workflow • More complicated clinical questions are arising that may require multi-omics-based clinical diagnostic assays • Issues in translating diagnostic data from preclinical to translational to clinical use • Transition points of the…Read more

day: Day 2 Track A PM

Harnessing Next Generation Digital Pathology to Advance Biomarker Discovery Using New Technologies & Tools 11:40 am

Immune oncology therapies work through complex mechanisms requiring coordinated responses involving multiple classes of cells and activation states over time. The identification of biomarkers to inform drug development, clinical trials, and selection of patients in the clinic cannot be done as it has been in the past Emerging tools and techniques have dramatically altered the…Read more

day: Day 1 Track A AM